UA73287C2 - Ciprofloxacin formulation with delayed release - Google Patents

Ciprofloxacin formulation with delayed release Download PDF

Info

Publication number: UA73287C2
Authority: UA; Ukraine
Prior art keywords: drug; tablets; composition; gas; pharmaceutical composition
Prior art date: 1998-09-14

Application number

UA2001031727A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Ranbaxy Lab Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-14

Filing date

1999-01-19

Publication date

2005-07-15

1998-09-14 Priority claimed from US09/152,932 external-priority patent/US6261601B1/en

1999-01-19 Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd

2005-07-15 Publication of UA73287C2 publication Critical patent/UA73287C2/uk

Links

MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 title claims abstract description 39
229960003405 ciprofloxacin Drugs 0.000 title claims abstract description 20
239000000203 mixture Substances 0.000 title claims description 75
238000009472 formulation Methods 0.000 title claims description 12
230000003111 delayed effect Effects 0.000 title 1
229920000642 polymer Polymers 0.000 claims abstract description 27
239000002775 capsule Substances 0.000 claims abstract description 26
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 17
235000010413 sodium alginate Nutrition 0.000 claims abstract description 16
239000000661 sodium alginate Substances 0.000 claims abstract description 16
229940005550 sodium alginate Drugs 0.000 claims abstract description 16
239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 13
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 13
229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 13
235000010493 xanthan gum Nutrition 0.000 claims description 14
239000000230 xanthan gum Substances 0.000 claims description 14
229920001285 xanthan gum Polymers 0.000 claims description 14
229940082509 xanthan gum Drugs 0.000 claims description 14
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
238000013270 controlled release Methods 0.000 claims description 2
239000008023 pharmaceutical filler Substances 0.000 claims 2
238000012876 topography Methods 0.000 claims 1
239000003814 drug Substances 0.000 abstract description 118
229940079593 drug Drugs 0.000 abstract description 113
239000003795 chemical substances by application Substances 0.000 abstract description 56
239000008194 pharmaceutical composition Substances 0.000 abstract description 41
230000008961 swelling Effects 0.000 abstract description 30
238000012377 drug delivery Methods 0.000 abstract description 29
210000002784 stomach Anatomy 0.000 abstract description 25
239000011159 matrix material Substances 0.000 abstract description 23
230000001225 therapeutic effect Effects 0.000 abstract description 9
150000001875 compounds Chemical class 0.000 abstract description 8
230000000717 retained effect Effects 0.000 abstract description 7
210000000813 small intestine Anatomy 0.000 abstract description 6
238000009792 diffusion process Methods 0.000 abstract description 4
230000002123 temporal effect Effects 0.000 abstract description 4
238000013268 sustained release Methods 0.000 abstract 1
239000012730 sustained-release form Substances 0.000 abstract 1
235000002639 sodium chloride Nutrition 0.000 description 28
150000003839 salts Chemical class 0.000 description 20
238000010521 absorption reaction Methods 0.000 description 19
239000002253 acid Substances 0.000 description 19
210000001035 gastrointestinal tract Anatomy 0.000 description 18
239000008187 granular material Substances 0.000 description 16
238000004090 dissolution Methods 0.000 description 15
239000004480 active ingredient Substances 0.000 description 11
239000012729 immediate-release (IR) formulation Substances 0.000 description 11
230000000694 effects Effects 0.000 description 10
239000000314 lubricant Substances 0.000 description 10
230000014759 maintenance of location Effects 0.000 description 10
210000002966 serum Anatomy 0.000 description 10
229920003169 water-soluble polymer Polymers 0.000 description 10
239000011248 coating agent Substances 0.000 description 9
238000000576 coating method Methods 0.000 description 9
239000012530 fluid Substances 0.000 description 9
-1 for example Substances 0.000 description 9
150000007513 acids Chemical class 0.000 description 8
235000010443 alginic acid Nutrition 0.000 description 8
229920000615 alginic acid Polymers 0.000 description 8
230000002496 gastric effect Effects 0.000 description 8
229920002785 Croscarmellose sodium Polymers 0.000 description 7
229960001126 alginic acid Drugs 0.000 description 7
239000000783 alginic acid Substances 0.000 description 7
239000000227 bioadhesive Substances 0.000 description 7
238000002156 mixing Methods 0.000 description 7
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 6
235000021152 breakfast Nutrition 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
229940126601 medicinal product Drugs 0.000 description 6
229940126701 oral medication Drugs 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
229960004150 aciclovir Drugs 0.000 description 5
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 5
239000000599 controlled substance Substances 0.000 description 5
230000006378 damage Effects 0.000 description 5
150000007524 organic acids Chemical class 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
239000006187 pill Substances 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
229920002125 Sokalan® Polymers 0.000 description 4
150000004781 alginic acids Chemical class 0.000 description 4
229910052783 alkali metal Inorganic materials 0.000 description 4
239000012736 aqueous medium Substances 0.000 description 4
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 4
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 4
239000000945 filler Substances 0.000 description 4
239000012458 free base Substances 0.000 description 4
229920001477 hydrophilic polymer Polymers 0.000 description 4
239000008101 lactose Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
238000000034 method Methods 0.000 description 4
229940124531 pharmaceutical excipient Drugs 0.000 description 4
239000013032 Hydrocarbon resin Substances 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229960001229 ciprofloxacin hydrochloride Drugs 0.000 description 3
DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical group Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 description 3
229920006270 hydrocarbon resin Polymers 0.000 description 3
235000012054 meals Nutrition 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000004584 polyacrylic acid Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical group OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 2
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
230000036765 blood level Effects 0.000 description 2
235000010410 calcium alginate Nutrition 0.000 description 2
239000000648 calcium alginate Substances 0.000 description 2
229960002681 calcium alginate Drugs 0.000 description 2
229910001424 calcium ion Inorganic materials 0.000 description 2
OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
229960000830 captopril Drugs 0.000 description 2
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
150000004649 carbonic acid derivatives Chemical class 0.000 description 2
230000008859 change Effects 0.000 description 2
235000015165 citric acid Nutrition 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
229960005316 diltiazem hydrochloride Drugs 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
235000020937 fasting conditions Nutrition 0.000 description 2
235000013305 food Nutrition 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
229940093915 gynecological organic acid Drugs 0.000 description 2
235000003642 hunger Nutrition 0.000 description 2
230000036571 hydration Effects 0.000 description 2
238000006703 hydration reaction Methods 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
230000003285 pharmacodynamic effect Effects 0.000 description 2
239000011148 porous material Substances 0.000 description 2
238000003825 pressing Methods 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
238000009490 roller compaction Methods 0.000 description 2
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
238000007873 sieving Methods 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
230000037351 starvation Effects 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
210000002438 upper gastrointestinal tract Anatomy 0.000 description 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000010564 aerobic fermentation Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229960003767 alanine Drugs 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
229960003459 allopurinol Drugs 0.000 description 1
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
235000010407 ammonium alginate Nutrition 0.000 description 1
239000000728 ammonium alginate Substances 0.000 description 1
KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
229960003022 amoxicillin Drugs 0.000 description 1
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000002579 anti-swelling effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000002255 antigout agent Substances 0.000 description 1
229960002708 antigout preparations Drugs 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003699 antiulcer agent Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
229960004099 azithromycin Drugs 0.000 description 1
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
229960000794 baclofen Drugs 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
235000019658 bitter taste Nutrition 0.000 description 1
229960002802 bromocriptine Drugs 0.000 description 1
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
235000010376 calcium ascorbate Nutrition 0.000 description 1
239000011692 calcium ascorbate Substances 0.000 description 1
229940047036 calcium ascorbate Drugs 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
239000001354 calcium citrate Substances 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000002327 cardiovascular agent Substances 0.000 description 1
229940125692 cardiovascular agent Drugs 0.000 description 1
229960004841 cefadroxil Drugs 0.000 description 1
NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
229960002420 cefatrizine Drugs 0.000 description 1
ACXMTAJLYQCRGF-PBFPGSCMSA-N cefatrizine Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC1=CN=N[N]1 ACXMTAJLYQCRGF-PBFPGSCMSA-N 0.000 description 1
229960002129 cefixime Drugs 0.000 description 1
OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
229960005090 cefpodoxime Drugs 0.000 description 1
WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
229960001668 cefuroxime Drugs 0.000 description 1
JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
229960003291 chlorphenamine Drugs 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
229940068183 ciprofloxacin 100 mg Drugs 0.000 description 1
229960002626 clarithromycin Drugs 0.000 description 1
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
238000013267 controlled drug release Methods 0.000 description 1
229920006037 cross link polymer Polymers 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
FYGDTMLNYKFZSV-MRCIVHHJSA-N dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 description 1
229960001985 dextromethorphan Drugs 0.000 description 1
229960004166 diltiazem Drugs 0.000 description 1
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
RRPFCKLVOUENJB-UHFFFAOYSA-L disodium;2-aminoacetic acid;carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.NCC(O)=O RRPFCKLVOUENJB-UHFFFAOYSA-L 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
229940005501 dopaminergic agent Drugs 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229960005293 etodolac Drugs 0.000 description 1
XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
229960001596 famotidine Drugs 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
229960003592 fexofenadine Drugs 0.000 description 1
230000000641 filaricidal effect Effects 0.000 description 1
238000005187 foaming Methods 0.000 description 1
239000004088 foaming agent Substances 0.000 description 1
235000013373 food additive Nutrition 0.000 description 1
239000002778 food additive Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
239000000416 hydrocolloid Substances 0.000 description 1
230000002706 hydrostatic effect Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
229960004752 ketorolac Drugs 0.000 description 1
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229960001977 loracarbef Drugs 0.000 description 1
JAPHQRWPEGVNBT-UTUOFQBUSA-N loracarbef Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C([O-])=O)=O)[NH3+])=CC=CC=C1 JAPHQRWPEGVNBT-UTUOFQBUSA-N 0.000 description 1
229960004844 lovastatin Drugs 0.000 description 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000008025 pharmaceutical bulking agent Substances 0.000 description 1
DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
229960000395 phenylpropanolamine Drugs 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
150000004804 polysaccharides Chemical class 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000010408 potassium alginate Nutrition 0.000 description 1
239000000737 potassium alginate Substances 0.000 description 1
MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
229960003908 pseudoephedrine Drugs 0.000 description 1
210000001187 pylorus Anatomy 0.000 description 1
229960000620 ranitidine Drugs 0.000 description 1
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
229960001520 ranitidine hydrochloride Drugs 0.000 description 1
GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical group [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
239000002151 riboflavin Substances 0.000 description 1
235000019192 riboflavin Nutrition 0.000 description 1
229960002477 riboflavin Drugs 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
229940043230 sarcosine Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000009738 saturating Methods 0.000 description 1
229960002855 simvastatin Drugs 0.000 description 1
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
229940125706 skeletal muscle relaxant agent Drugs 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
235000010378 sodium ascorbate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
235000013337 tricalcium citrate Nutrition 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Oncology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Obesity (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Nutrition Science (AREA)
Transplantation (AREA)
Cardiology (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Child & Adolescent Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Physiology (AREA)
Epidemiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

UA2001031727A 1998-09-14 1999-01-19 Ciprofloxacin formulation with delayed release UA73287C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/152,932 US6261601B1 (en)	1997-09-19	1998-09-14	Orally administered controlled drug delivery system providing temporal and spatial control
PCT/IB1999/000078 WO2000015198A1 (en)	1998-09-14	1999-01-19	Orally administered controlled drug delivery system providing temporal and spatial control

Publications (1)

Publication Number	Publication Date
UA73287C2 true UA73287C2 (en)	2005-07-15

Family

ID=22545063

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2001031727A UA73287C2 (en)	1998-09-14	1999-01-19	Ciprofloxacin formulation with delayed release

Country Status (40)

Country	Link
EP (2)	EP1107741B1 (de)
JP (1)	JP2002524494A (de)
CN (1)	CN1186013C (de)
AP (1)	AP1659A (de)
AR (1)	AR022672A1 (de)
AT (1)	ATE245414T1 (de)
AU (1)	AU758324B2 (de)
BG (1)	BG105339A (de)
BR (1)	BR9913696A (de)
CA (1)	CA2343760A1 (de)
CO (1)	CO5130022A1 (de)
CU (1)	CU23040A3 (de)
CZ (1)	CZ2001901A3 (de)
DE (1)	DE69909801T2 (de)
DK (1)	DK1107741T3 (de)
EA (2)	EA004443B1 (de)
EE (1)	EE200100153A (de)
ES (1)	ES2204098T3 (de)
GE (1)	GEP20043216B (de)
HR (1)	HRP20010187B1 (de)
HU (1)	HUP0103632A3 (de)
ID (1)	ID29843A (de)
IL (1)	IL141977A0 (de)
IS (1)	IS5885A (de)
MX (1)	MXPA01002634A (de)
MY (1)	MY127952A (de)
NO (1)	NO20011276L (de)
NZ (2)	NZ523747A (de)
OA (1)	OA11652A (de)
PE (1)	PE20001058A1 (de)
PL (1)	PL346798A1 (de)
PT (1)	PT1107741E (de)
SI (1)	SI1107741T1 (de)
SK (1)	SK285478B6 (de)
SV (1)	SV1999000152A (de)
TR (1)	TR200100731T2 (de)
UA (1)	UA73287C2 (de)
UY (1)	UY25710A1 (de)
WO (1)	WO2000015198A1 (de)
ZA (1)	ZA995839B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1263409A1 (de) *	2000-03-03	2002-12-11	Ranbaxy Laboratories, Limited	Oral anzuwendendes system mit gesteuerter wirkstoffabgabe zur einmal täglichen verabreichung von ciprofloxacin
AU2006202275A1 (en) *	2000-06-26	2006-06-22	Bayer Healthcare Ag	Sustained-release preparations of quinolone antibiotics and method for preparation thereof
DE10031043A1 (de)	2000-06-26	2002-02-14	Bayer Ag	Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
KR100878667B1 (ko) *	2000-08-08	2009-01-13	다이이찌 세이야꾸 가부시기가이샤	고흡수성 고형 제제
IN192748B (de) *	2000-08-29	2004-05-15	Ranbaxy Lab Ltd
WO2002045695A2 (en)	2000-12-05	2002-06-13	Alexander Macgregor	Hydrostatic delivery system for controlled delivery of agent
RU2325152C2 (ru) *	2001-07-04	2008-05-27	Сан Фармасьютикл Индастриз Лимитид	Удерживаемая в желудке система регулируемой доставки лекарственного средства
KR20040032918A (ko) *	2001-08-16	2004-04-17	더 스테이트 오브 오레곤 액팅 바이 앤드 쓰루 더 스테이트 보드 오브 하이어 에쥬케이션 온 비해프 오브 오레곤 스테이트 유니버시티	팽창 가능한 위 정지 장치
WO2003017981A1 (en) *	2001-08-29	2003-03-06	Ranbaxy Laboratories Limited	Controlled release formulation of clarithromycin or tinidazol
WO2003037296A2 (en) *	2001-10-29	2003-05-08	Labopharm Inc.	Methods and dosage forms for improving the bioavailability of therapeutic agents
CN100534531C (zh) *	2001-11-13	2009-09-02	山之内制药技术股份有限公司	可溶的药物缓释系统
ATE319434T1 (de) *	2001-11-19	2006-03-15	Lupin Ltd	Pharmazeutische zusammensetzung für die kontrollierte freisetzung eines beta-lactam- antibiotikums
US20050175694A1 (en) *	2002-04-23	2005-08-11	Himadri Sen	Long acting compositions comprising zidovudine and lamivudine
WO2005018613A1 (de) *	2003-08-26	2005-03-03	Mandapro Ag	Pellets für die orale applikation von pharmazeutischen wirkstoffen
CA2569919A1 (en) *	2004-06-28	2006-01-05	Solvay Pharmaceuticals B.V.	Oral sustained release formulation of tedisamil with gastric retention properties
DE102004042139B4 (de) *	2004-08-31	2009-06-10	Aristocon Verwaltungs- Gmbh	Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
GB0501810D0 (en) *	2005-01-28	2005-03-09	Pharmakodex Ltd	Chemotherapeutic formulations
US20090099154A1 (en) *	2005-06-29	2009-04-16	Panacea Biotec Ltd.	Pharmaceutical Sustained Release Compositions and Processes Thereof
EP1745775B1 (de) *	2005-07-19	2008-05-28	Ethypharm	Gastroretentive Zusammensetzungen und Verfahren zur Herstellung
GB0515492D0 (en) *	2005-07-28	2005-08-31	Reckitt Benckiser Healthcare	Improvements in or relating to compositions,articles and methods
KR20080076382A (ko) *	2007-02-15	2008-08-20	(주)아모레퍼시픽	실로스타졸의 제어방출 제제 및 그 제조방법
ZA200903854B (en) *	2008-06-19	2011-02-23	Univ Of The Witwatesrand Johannesburg	A gastroretentive pharmaceutical dosage form
JP2012500230A (ja)	2008-08-18	2012-01-05	北京天衡▲薬▼物研究院	胃内滞留薬物放出システム及びその製造方法と使用
WO2011125075A2 (en)	2010-04-08	2011-10-13	Fdc Limited	A novel gastroretentive delivery of macrolide
EP2415460A1 (de) *	2010-08-03	2012-02-08	ratiopharm GmbH	Orale Darreichungsform von Pregabalin
TWI705814B (zh) *	2014-06-20	2020-10-01	美商梅琳塔有限責任公司	醫藥組成物及其用途
CA2966937C (en) *	2014-11-19	2023-08-08	Fmc Corporation	Nanosuspension comprising low viscosity alginate with rapid release of active ingredients
US10987311B2 (en)	2017-06-16	2021-04-27	Kashiv Specialty Pharmaceuticals, Llc	Extended release compositions comprising pyridostigmine
US10588863B2 (en)	2017-06-16	2020-03-17	Kashiv Biosciences, Llc	Extended release compositions comprising pyridostigmine
US10918597B2 (en)	2017-06-16	2021-02-16	Kashiv Specialty Pharmaceuticals, Llc	Gastroretentive dosage forms for sustained drug delivery
EP3824881B1 (de)	2018-06-18	2022-02-16	Amneal Complex Products Research LLC	Pyridostigminhaltige zusammensetzungen mit verlängerter freisetzung
EP3970701B1 (de)	2018-06-27	2025-05-07	Amneal Complex Products Research LLC	Selbstregulierende osmotische gastroretentive arzneimittelabgabesysteme
CN110448535A (zh) *	2019-09-04	2019-11-15	湖南宇山玉月农业科技有限公司	一种裂褶菌素胃漂浮片
CN111116794A (zh) *	2019-12-20	2020-05-08	蚌埠市鑫晟新材料科技有限公司	一种中性造纸用聚合材料的制备方法
CN115715765A (zh) *	2021-08-24	2023-02-28	江苏万邦生化医药集团有限责任公司	一种悬浮片剂
CN113768898A (zh) *	2021-09-14	2021-12-10	江苏万邦生化医药集团有限责任公司	悬浮的胶囊片

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0798742B2 (ja) *	1986-07-03	1995-10-25	ゼリア新薬工業株式会社	徐放性製剤組成物
US5096714A (en) *	1988-06-28	1992-03-17	Hauser-Kuhrts, Inc.	Prolonged release drug tablet formulations
JPH0624959A (ja) *	1991-10-04	1994-02-01	Bayer Yakuhin Kk	胃内浮遊型薬物徐放性固形製剤

1999
- 1999-01-19 HU HU0103632A patent/HUP0103632A3/hu unknown
- 1999-01-19 AP APAP/P/2001/002098A patent/AP1659A/en active
- 1999-01-19 JP JP2000569782A patent/JP2002524494A/ja active Pending
- 1999-01-19 MX MXPA01002634A patent/MXPA01002634A/es not_active Application Discontinuation
- 1999-01-19 EA EA200100346A patent/EA004443B1/ru not_active IP Right Cessation
- 1999-01-19 SI SI9930376T patent/SI1107741T1/xx unknown
- 1999-01-19 TR TR2001/00731T patent/TR200100731T2/xx unknown
- 1999-01-19 ID IDW20010594A patent/ID29843A/id unknown
- 1999-01-19 EA EA200300847A patent/EA005767B1/ru not_active IP Right Cessation
- 1999-01-19 DE DE69909801T patent/DE69909801T2/de not_active Expired - Fee Related
- 1999-01-19 AT AT99900106T patent/ATE245414T1/de not_active IP Right Cessation
- 1999-01-19 SK SK347-2001A patent/SK285478B6/sk unknown
- 1999-01-19 CZ CZ2001901A patent/CZ2001901A3/cs unknown
- 1999-01-19 CU CU20010067A patent/CU23040A3/es unknown
- 1999-01-19 EE EEP200100153A patent/EE200100153A/xx unknown
- 1999-01-19 CN CNB998129887A patent/CN1186013C/zh not_active Expired - Fee Related
- 1999-01-19 NZ NZ523747A patent/NZ523747A/en unknown
- 1999-01-19 IL IL14197799A patent/IL141977A0/xx unknown
- 1999-01-19 UA UA2001031727A patent/UA73287C2/uk unknown
- 1999-01-19 EP EP99900106A patent/EP1107741B1/de not_active Expired - Lifetime
- 1999-01-19 WO PCT/IB1999/000078 patent/WO2000015198A1/en not_active Ceased
- 1999-01-19 BR BR9913696-1A patent/BR9913696A/pt not_active IP Right Cessation
- 1999-01-19 CA CA002343760A patent/CA2343760A1/en not_active Abandoned
- 1999-01-19 NZ NZ510487A patent/NZ510487A/xx unknown
- 1999-01-19 GE GEAP19995796A patent/GEP20043216B/en unknown
- 1999-01-19 EP EP02023169A patent/EP1281397A1/de not_active Withdrawn
- 1999-01-19 HR HR20010187A patent/HRP20010187B1/xx not_active IP Right Cessation
- 1999-01-19 AU AU17794/99A patent/AU758324B2/en not_active Ceased
- 1999-01-19 ES ES99900106T patent/ES2204098T3/es not_active Expired - Lifetime
- 1999-01-19 OA OA1200100064A patent/OA11652A/en unknown
- 1999-01-19 DK DK99900106T patent/DK1107741T3/da active
- 1999-01-19 PT PT99900106T patent/PT1107741E/pt unknown
- 1999-01-19 PL PL99346798A patent/PL346798A1/xx unknown
- 1999-09-10 ZA ZA9905839A patent/ZA995839B/xx unknown
- 1999-09-13 MY MYPI99003949A patent/MY127952A/en unknown
- 1999-09-13 PE PE1999000924A patent/PE20001058A1/es not_active Application Discontinuation
- 1999-09-13 SV SV1999000152A patent/SV1999000152A/es not_active Application Discontinuation
- 1999-09-14 UY UY25710A patent/UY25710A1/es unknown
- 1999-09-14 CO CO99058020A patent/CO5130022A1/es unknown
- 1999-09-17 AR ARP990104682A patent/AR022672A1/es not_active Application Discontinuation
2001
- 2001-03-12 IS IS5885A patent/IS5885A/is unknown
- 2001-03-13 BG BG105339A patent/BG105339A/xx unknown
- 2001-03-13 NO NO20011276A patent/NO20011276L/no unknown

Also Published As

Publication number	Publication date
HK1037967A1 (en)	2002-03-01
SK285478B6 (sk)	2007-02-01
HUP0103632A3 (en)	2005-06-28
JP2002524494A (ja)	2002-08-06
UY25710A1 (es)	2000-03-31
HRP20010187A2 (en)	2002-04-30
AP2001002098A0 (en)	2001-03-31
PE20001058A1 (es)	2000-10-05
SV1999000152A (es)	2000-07-03
AP1659A (en)	2006-09-06
GEP20043216B (en)	2004-04-26
SK3472001A3 (en)	2001-10-08
EP1107741A1 (de)	2001-06-20
DK1107741T3 (da)	2003-11-17
IL141977A0 (en)	2002-03-10
HUP0103632A2 (hu)	2002-02-28
AU758324B2 (en)	2003-03-20
CN1325299A (zh)	2001-12-05
TR200100731T2 (tr)	2001-06-21
PT1107741E (pt)	2003-12-31
DE69909801T2 (de)	2004-06-03
WO2000015198A1 (en)	2000-03-23
NZ523747A (en)	2004-04-30
ATE245414T1 (de)	2003-08-15
EP1281397A1 (de)	2003-02-05
NZ510487A (en)	2003-04-29
NO20011276D0 (no)	2001-03-13
ID29843A (id)	2001-10-18
PL346798A1 (en)	2002-02-25
OA11652A (en)	2004-12-08
EA200300847A1 (ru)	2003-12-25
CN1186013C (zh)	2005-01-26
EE200100153A (et)	2002-06-17
AU1779499A (en)	2000-04-03
EP1107741B1 (de)	2003-07-23
IS5885A (is)	2001-03-12
EA004443B1 (ru)	2004-04-29
BG105339A (en)	2001-11-30
ZA995839B (en)	2000-03-28
CO5130022A1 (es)	2002-02-27
ES2204098T3 (es)	2004-04-16
CZ2001901A3 (cs)	2001-08-15
NO20011276L (no)	2001-05-10
DE69909801D1 (de)	2003-08-28
BR9913696A (pt)	2001-10-09
SI1107741T1 (en)	2004-02-29
MXPA01002634A (es)	2002-06-04
CA2343760A1 (en)	2000-03-23
HRP20010187B1 (en)	2004-04-30
EA200100346A1 (ru)	2001-10-22
AR022672A1 (es)	2002-09-04
MY127952A (en)	2007-01-31
EA005767B1 (ru)	2005-06-30
CU23040A3 (es)	2005-04-14

Publication	Publication Date	Title
UA73287C2 (en)	2005-07-15	Ciprofloxacin formulation with delayed release
KR100642110B1 (ko)	2006-11-10	시간적 및 공간적 조절을 제공하는 경구투여용 제어 약물 전달 시스템
EP0795324B1 (de)	2004-04-21	Eine pharmazeutische Tablette charakterisiert durch hohen Volumenzuwachs bei Kontakt mit biologischen Flüssigkeiten
US5292518A (en)	1994-03-08	Prolonged-release drug tablet formulations
US6476006B2 (en)	2002-11-05	Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
JPH10511407A (ja)	1998-11-04	高用量難溶性薬物用持続放出マトリックス
MXPA02008568A (es)	2003-02-24	Sistema de suministro controlado oralmente administrado para administracion de una vez al dia de ciprofloxacina.
AU2014368504B2 (en)	2019-12-19	Gastro-retentive oral pharmaceutical compositions
TWI229609B (en)	2005-03-21	Pharmaceutical composition of orally administered controlled drug delivery system providing temporal and spatial control
HK1053422A (en)	2003-10-24	Orally administered controlled drug delivery system providing temporal and spatial control
AU2006201553A1 (en)	2006-05-11	Orally administered controlled delivery system for once daily administration of ciprofloxacin